[Clinical studies on XXXX fine granule in pediatric field].

@entity1 @entity3617 @entity1712 @entity526 @entity7551 @entity5609 @entity2348 @entity5389 @entity2688 @entity794 @entity4195 @entity281 @entity869 @entity7265 @entity7576 @entity5899 @entity2335 @entity30773
Pharmacokinetics, safety and effects on @entity2348 of @entity7576 (SBTPC) fine granule were evaluated in 17 @entity1 . The results obtained are summarized as follows. 1. Pharmacokinetics in 3 @entity1 receiving a single dose of 10 mg per kg body weight were evaluated. The half-life of @entity869 (ABPC) was 1.38 +/- 0.14 hours and that of @entity5899 was 0.93 +/- 0.26 hour. 2. Fourteen cases, including 7 @entity5389 , 2 @entity7551 , 2 @entity3617 , and 1 each of @entity2335 , @entity30773 and @entity2688 were treated with SBTPC fine granule. The clinical efficacy rate was 100%. 3. Bacteriological efficacies classified by causative organisms were evaluated in 5 @entity1 . @entity794 was responsible in 3 cases, @entity4195 in 1 case, @entity526 and @entity5609 in 1 case. Eradication rate was 100%. SBTPC was more active than ABPC against ABPC-resistant strains and almost equal to or more active than @entity7265 or cefaclor. 4. The only abnormal laboratory test value observed was @entity1712 in 2 @entity1 . No side effects were recorded. From the above results it is concluded that SBTPC fine granule is one of first choices of effective, useful and safe antibiotics for the treatment of @entity281 in pediatric field.
